InsidersTradesSigma
Explore the full management transaction log of PALVELLA THERAPEUTICS, INC., a listed equity based in United States. Shares trade on US US, under the authority of SEC (Form 4). Market capitalisation: €1.8bn. The latest transaction was reported on 10 April 2025 (Acquisition). Among the most active insiders: JENKINS GEORGE M. All data is openly available.
Analysts rate PALVELLA THERAPEUTICS, INC. Strong Buy (bullish), based on 10 analysts. Average price target: US$57.10.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
3 of 3 declarations
PALVELLA THERAPEUTICS, INC. is a company focused on developing treatments for autoimmune diseases. It is listed on NASDAQ under the ticker XNAS.